247 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

You can select a specific type of a publication you are looking for, such as press releases or speeches

Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma

Zorginstituut Nederland has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment ...

Report | 29-05-2019

Explanation of the Interest Form - CBG-ZIN Parallel Procedures pilot

Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...

Publication | 09-05-2019

Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)

Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...

Report | 08-05-2019

Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis

Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal product ...

Report | 24-04-2019

Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults

Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the ...

Report | 16-04-2019

Pitolisant (Wakix®) for the treatment of narcolepsy in adults

Zorginstituut Nederland carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug currently ...

Report | 15-04-2019

Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea

Zorginstituut Nederland carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is interchangeable with ...

Report | 09-04-2019

Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions

Zorginstituut Nederland carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be altered. ...

Report | 02-04-2019

Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally ...

Report | 01-04-2019

Organisation structure National Health Care Institute

Publication | 26-03-2019